LUND, Sweden, June 4, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology
(Spotlight, Sweden: SCOL), today announced signing of a
collaboration agreement. The two companies have agreed to explore
the anti-tumor efficacy of the CD40 antibody mitazalimab (Alligator
Bioscience) in combination with SCO-101 (Scandion Oncology) as an
addition to chemotherapy in resistant preclinical tumor models. The
expectation is that SCO-101 will revert chemotherapy resistance and
thereby further strengthening the anti-tumor effects of
mitazalimab.
Immuno-oncology (IO) drugs have proven very effective in subsets
of cancer patients. Recently, data from large clinical trials have
shown that the combination of IO drugs and standard chemotherapy
results in additive anti-tumor effects and more durable remissions
in cancer patients. However, many cancers develop resistance to
chemotherapy and consequently, no additive effects will be expected
in these patients.
The Alligator Bioscience drug candidate mitazalimab enhances
presentation of antigens released by cancer cells and is thought to
be beneficial in combination with chemotherapy, where large amounts
of antigens are being released by dying tumor cells. Scandion
Oncology's drug candidate SCO-101 acts by blocking resistance
mechanisms in cancer cells, allowing chemotherapy to kill
previously resistant cancer cells. Thereby, SCO-101 would restore
the release of antigens and re-activate the anti-cancer effects of
the IO drugs.
"This collaboration will further validate mitazalimab's
potential in combination therapy with diverse chemotherapeutic
agents, as well as the power of SCO-101 as a solution to the
widespread issue of chemoresistance," said Per Norlén, CEO
of Alligator Bioscience.
"This is a dream scenario for Scandion Oncology. Combinations
between SCO-101, chemotherapy and an IO drug like mitazalimab could
easily become the future of anti-cancer therapy" says Nils Brünner,
CEO of Scandion Oncology.
Results from the studies in this collaboration are expected
during first half of 2021.
This information is such information as Alligator Bioscience
AB (publ) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact person set out above, at 2:00
p.m. CEST on June 4,
2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company
developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes six lead clinical and preclinical
drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527
(co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical
development by Shanghai Henlius Biotech Inc.). Alligator's shares
are listed on Nasdaq Stockholm (ATORX). The Company is
headquartered in Lund, Sweden. For
more information, please visit www.alligatorbioscience.com.
About Scandion Oncology
Scandion Oncology A/S is a clinical-stage biotechnology company
that addresses one of the greatest challenges in modern oncology -
the effective treatment of cancer which contains
chemotherapy-resistant cells, or which has developed resistance to
a previously prescribed cancer drug. Scandion Oncology is now in
clinical phase II trials with its lead compound, SCO-101, in
patients with chemotherapy-resistant colorectal cancer. In addition
to SCO-101 the Company has two other drug candidates, SCO-201 and
SCO-301. Scandion Oncology was listed on Spotlight Stock Market,
Sweden in November 2018. For more information, please visit
www.scandiononcology.com.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-and-scandion-oncology-sign-preclinical-agreement-to-explore-combination-therapi,c3127995
The following files are available for download:
https://mb.cision.com/Main/12681/3127995/1259221.pdf
|
Alligator Bioscience
and Scandion Oncology sign preclinical agreement to explore
combination therapies for chemotherapy and
immuno-oncology
|